Corporate Accountability

Congress Holding Hearing on CFPB Constitutionality

By Jann Swanson

The House Financial Services Committee has scheduled a hearing on March 21 titled “The Bureau of Consumer Financial Protection’s (CFPB’s) Unconstitutional Design.”  The hearing comes on the heels of a decision by the Department of Justice to not defend the Bureau in a landmark case brought to PHH challenging the constitutionality of CFPB’s structure.

The Committee’s majority memorandum states, “This hearing will examine whether the structure of the Bureau of Consumer Financial Protection (“Bureau”) violates the Constitution as well as structural changes to the Bureau to resolve any constitutional infirmities. As established by the Dodd-Frank Wall Street Reform and Consumer Protection Act (Pub. L. No. 111-203) (“Dodd-Frank”), the Bureau is headed by a single Director who serves a term of five years and is removable by the President “for inefficiency, neglect of duty, or malfeasance in office.” Under Dodd Frank, the Director sets the Bureau’s budget; the Bureau is funded outside of the congressional appropriations process through transfers from the Federal Reserve System’s operating expenses, subject to a statutory cap.

Scheduled to appear as witnesses are The Honorable Theodore Olson, Partner, Gibson, Dunn & Crutcher LLP who is the lead counsel for PHH in its suit, Professor Saikrishna Prakash, James Monroe Distinguished Professor, University of Virginia School of Law; Adam White, Research Fellow, Hoover Institution; and Brianne Gorod, Chief Counsel, Constitutional Accountability Center.

Alan S. Kaplinsky, an attorney with Ballard & Spahr, a firm that closely monitors CFPB activity, writes in the firms blog that tomorrow’s hearing will undoubtedly cover the same constitutional issues that will be argued before the Circuit Court for the District of Colombia in May in PHH Corporation v CFPB.  

Committee Chairman Jeb Hensarling (R-TX) in a press release, applauded the Justice Department’s decision to support PHH in its suit, saying in part, “Republicans have said for years that the Bureau is unconstitutionally structured.  Its lack of accountability and the unparalleled authority placed in the hands of the Bureau’s unaccountable sole director make the CFPB arguably the most powerful and least accountable bureaucracy in American history.”

More from Corporate Accountability

Corporate Accountability
September 9, 2025

ENFORCEMENT ACTIONS—Fifth Circuit rejects petition challenging OCC authority to enforce national banking rules

Wolters Kluwer VitalLaw
The court distinguished the national banking regulatory regime from the SEC’s antifraud provision in Jarkesy and the...
Corporate Accountability
July 11, 2025

This Group’s Record in Front of the Roberts Court Is Mind-Boggling

Slate
In a provocative dissenting opinion, Justice Ketanji Brown Jackson recently called out her colleagues on the Supreme Court...
By: Ana Builes, Brian R. Frazelle
Corporate Accountability
July 2, 2025

Moneyed Interests Still Prevail at the Supreme Court (2024-2025 Term)

The Court Continues to Favor Corporations over Workers, Consumers, and the Environment.
By: Brian R. Frazelle, Ana Builes
Corporate Accountability
U.S. Court of Appeals for the Third Circuit

Novartis v. Secretary United States Department of Health and Human Services

In Novartis v. Secretary United States Department of Health and Human Services, the United States Court of Appeals for the Third Circuit considered whether the Inflation Reduction Act’s Medicare drug price negotiation program is an unconstitutional...
Corporate Accountability
January 28, 2025

Federal Deposit Insurance as Jarkesy Waiver

Yale Journal on Regulation
An argument lurking just beneath the surface in a pending Fifth Circuit case could stem...
Corporate Accountability
U.S. Court of Appeals for the Second Circuit

Boehringer Ingelheim v. Department of Health and Human Services

In Boehringer Ingelheim v. Department of Health and Human Services, the United States Court of Appeals for the Second Circuit considered whether the Inflation Reduction Act’s Medicare drug price negotiation program is an unconstitutional taking...